Date of Release: September 17, 2021

Expiration Date: September 17, 2023

Credits offered: CME

Estimate time of completion: 12 hours

Course must be completed by the expiration date are reported one time.

www.acmgeducation.net

Course Description

The 2021 New York Mid-Atlantic Caribbean (NYMAC) Regional Genetic Network Annual Meeting: Expanding Access to Genetic Services- Collaboration, Communication, and Connection brings together a diverse group of stakeholders will explore strategies that can impact access to patient centered genetics care. Topics include interprofessional collaboration, telegenetics, engagement with and learning from families and family organizations, cultural dexterity and social determinants of health, quality improvement, and collaborating locally to address unique barriers to care. New policies in areas such as telehealth and new technologies in genomic testing and data sharing also be reviewed and related to access goals.

Target Audience

With an explicit goal of including diverse stakeholders, the intended audience includes families impacted by genetic conditions, family organizations, physicians and other health care providers and trainees, public health organizations, NYMAC collaborators, federal and local representatives, industry and insurance parties, and other groups whose work impacts or is impacted by genetic services. 

Learning Objectives

At the conclusion of this activity, participants should be able to:

1. Summarize several of the well-curated resoures on genetic topics and conditions available to primary care providers that can be used througout the referral process and in manging patients with genetic conditions.
2. List opportunities for broader engagement of providers, families, and public health entitites with family organizations.
3. Identify opportunities for new collaborations between NYMAC and your organization.

Continuing Education Information

CME Educational Credits 

Continuing Medical Education (CME)
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The American College of Medical Genetics and Genomics and the NYMAC Regional Genetics Network.

Credit Designation
The American College of Medical Genetics and Genomics designates this enduring activity for a maximum of 12 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country.

Non-physicians may request a certificate of attendance for their participation.

Participation Instructions (OnDemand)

1. Complete session by watching recordings.
2. Pass a post-test with a score of 80% or better (Learning mode activated and reset).
3. Complete session evaluations.

Content Validation and Fair Balance

1. ACMG follows the ACCME policy on Content Validation for CME activities, which requires:
2. a) All recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients.
3. b) All scientific research referred to, reported or used in CME in support or justification of patient care recommendations must conform to the generally accepted standards of experimental design, data collection and analysis.
4. Activities that fall outside the definition of CME/CE; “Educational activities that serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession” (source: ACCME and AMA) will not be certified for credit. CME activities that promote recommendations, treatment, or manners of practicing medicine or pharmacy that are not within the definition of CME/CE or, are known to have risks or dangers that outweigh the benefits or, are known to be ineffective in the treatment of patients.
5. Presentations and CME/CE activity materials must give a balanced view of therapeutic options; use of generic names will contribute to this impartiality. If the CME/CE educational materials or content includes trade names, where available, trade names from several companies must be used.

Off-Label Uses of Products

When an off-label use of a product, or an investigational use not yet approved for any purpose, is discussed during an educational activity, the accredited sponsor shall require the speaker to disclose that the product is not labeled for the use under discussion, or that the product is still investigational. Discussions of such uses shall focus on those uses that have been subject of objective investigation.

HIPAA Compliance by Faculty

The ACMG supports medical information privacy. While the ACMG is not a “covered entity” under HIPAA 1996 and therefore is not required to meet these standards, ACMG wishes to take reasonable steps to ensure that the presentation of individually identifiable health information at ACMG-sponsored events has been properly authorized. All presenters have completed a form indicating whether they intend to present any form of individually identifiable healthcare information. If so, they were asked either to at that a HIPAA-compliant consent form is on file at their institution, or to send ACMG a copy of the HIPAA compliance form. This information is on record at the ACMG Administrative Office and will be made available upon request.

Disclaimer

ACMG educational programs are designed primarily as an educational tool for health care providers who wish to increase their understanding of the application of genomic technologies to patient care. The ACMG does not endorse or recommend the use of this educational program to make patient diagnoses, particular by individuals not trained in medical genetics. Adherence to the information provided in these programs does not necessarily ensure a successful diagnostic outcome. The program should not be considered inclusive of all proper procedures and s or exclusive of other procedures and s that are reasonably directed at obtaining the same results. In determining the propriety of any specific procedure or, a healthcare provider should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.

Questions regarding CE credit should be directed to education@acmg.net.

Funding Disclaimer
This meeting is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $600,000 with 0 percent financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov.
CME funding is supported by the National Coordinating Center for the Regional Genetics Networks (NCC). The NCC is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under Cooperative Agreement #UH9MC30770 from 6/2020-5/2024 for $800,000 per award year. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government.

Financial Disclosures

Disclosure Statement

It is the policy of the American College of Medical Genetics and Genomics to plan and implement all of its educational activities in accordance with the ACCME Essentials and Areas and ACCME® Policies to ensure balance, independence, objectivity and scientific rigor. In accordance with the ACCME® Standards for Commercial Support, everyone (speakers, moderators, committee members and staff) who is in a position to control the content of an educational activity certified for AMA PRA Category 1 Credit™ is required to disclose all financial relationships with any ineligible company within the past 24 months that creates a real or apparent conflict of interest. Individuals who do not disclose will be disqualified from participating in a CME activity.

This disclosure pertains to relationships with ACCME-defined commercial interests whose products or services may be related to the subject matter of the presentation topic. Any real or apparent conflicts of interest related to the content of the presentations must be managed prior to the educational activity. ACMG will identify, review and resolve all conflicts of interests prior to an educational activity being delivered to learners.

NOTE:

• ACMG will follow the ACCME’s expectation that no employees or owners of commercial interests will be involved as planners/faculty/presenters of a CME accredited activity.
• The ACCME definition of a commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
• The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.
• Diagnostic laboratories are not considered commercial interests unless they are owned by or have a sister organization which is a commercial interest.

The following reported disclosures and none are relevant to the content of this course. All of the relevant financial relationships listed for these individuals have been mitigated.

Planning Committee and ACMG Staff*

The following have nothing to disclose.

Joann Bodurtha, MD, MPH, FACMG (Moderator)

Michele Caggana, ScD, FACMG

Luba Djurdjinovic, MS

Patricia Bish

Alissa Bovee Terry, ScM, CGC

Andrea Durst, MS, DrPH, LCGC

Melissa Raspa, PhD

Roseani Sanchez Algarin, MA

Maria Isabel Frangenberg, BA

Presenters have nothing to disclose: